Innovative Drug Delivery Systems, Inc. (IDDS) To Host Conference Call To Discuss Positive Pivotal Phase II/III Dyloject(TM) Results
10/19/2005 5:09:00 PM
NEW YORK--(BUSINESS WIRE)--July 25, 2005--Intrac, Inc. (OTC BB: ITRD.OB) and its wholly-owned subsidiary Innovative Drug Delivery Systems (IDDS) will host a conference call on Tuesday, July 26, 2005 beginning at 10:00 AM EDT to discuss the recently reported pivotal European Phase II/III study of Dyloject(TM) (diclofenac sodium injection). Results from the study demonstrated that Dyloject provided superior pain relief over 4 hours compared to placebo and therapeutic non-inferiority to Voltarol(R). These findings were the primary endpoints necessary to meet requirements for the Marketing Authorization Approval of Dyloject(TM). Additionally, preliminary analysis of the data did not reveal any unexpected safety signals and reported incidents of phlebitis in patients receiving Dyloject were half the rate of Voltarol.
IDDS invites all those interested in hearing management's discussion of the Phase II/III study results to join the call by dialing (877) 407-9210 for domestic participants or (201) 689-8049 for international participants. Participants are asked to call the above numbers 5-10 minutes prior to the starting time.
comments powered by